Newly Released Canadian Data Links Vaccines with Pervasive,Developmental Disorder ( National Autism Association calls 2006 ...)

Newly Released Canadian Data Links Vaccines with Pervasive,Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatally flawed

CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findings presented yesterday at a National Autism Association meeting bolster claims that vaccines may play a role in the development of autism spectrum disorders. David Ayoub, MD presented data suggesting a correlation between mercury- containing vaccines and rates of pervasive developmental disorder (PDD), a form of autism, in Montreal. The peak rate of one in 87 children diagnosed with PDD occurred following the period of greatest exposure to the mercury- based vaccine preservative thimerosal. A flattening of the rates studied is now emerging as mercury-containing vaccines have been gradually eliminated from the routine schedule.

This new data points out flaws in a 2006 study published in the journal Pediatrics by Eric Fombonne, MD, et al, which found PDD rates continued to increase even when rates of MMR vaccination and use of mercury-containing vaccines decreased. The study population consisted of a single Montreal school board that was an Autism Center of Excellence, suggesting an over- ascertainment of regional diagnoses. Dr. Ayoub and co-authors Monica Ruscitti, BA, and F. Edward Yazbak, MD broadened the data to include all five Montreal school boards.

The earlier study also reported PDD rates in children from Montreal, but MMR coverage data was taken from Quebec City located 265km from Montreal. The researchers confirmed MMR coverage rates actually increased in Montreal along with PDD, noting a sharper rise in rates after the number of required MMR shots doubled.

The Pediatrics paper claimed there was no exposure to mercury from vaccines post-1996 although several mercury-containing vaccines were administered well beyond 1996. "It's irresponsible that such flawed data was published in a medical journal. This new information confirms a relationship between va
'"/>

Page: 1 2
Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 /PRNewswire-iReach/ -- The 2013 ... NJ has attracted the greatest number of "Emerging" ... President, Mark Alexay . "No ... to attend this year. The show,s still 4 months ... companies. This is a big surprise and great ...

(Date:5/21/2013)... , May 21, 2013 Decision ... and advisory firms for pharmaceutical and healthcare ... emerging agent on key efficacy endpoints, including ... has the most influence over surveyed U.S. ... hormone-receptor (HR-) positive, HER2-negative breast cancer. The ...

(Date:5/21/2013)... , May 21, 2013 IsoRay, Inc. (AMEX: ... it has entered into an exclusive international distribution agreement ... product line in Greece . IsoRay ... brachytherapy and medical radioisotope applications for brain cancer, lung ... ("gyn") cancer. IASIS Medical is ideally ...

Breaking Medicine Technology:Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2 Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2 IsoRay Announces A New International Distributor For Greece 2 IsoRay Announces A New International Distributor For Greece 3

[0] Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show [0] Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer [0] IsoRay Announces A New International Distributor For Greece

... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...

... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...

Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4

NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients

(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...

(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and the ... Wellness Fair to educate the public on health initiatives and ... Wednesday, May 22, 2013 from 4:00 pm until 7:00 pm ... Creek Road, Charlotte, NC 29262). , Medic, the ... Mecklenburg County Department of Social Services are working toward ...

(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...

(Date:5/21/2013)... According to a May 13, 2013 New Zealand ... Botox injections have become the most popular cosmetic ... to goo.gl/8iYbD). Although it is mostly associated with women, ... makes facial wrinkles less visible by paralyzing facial muscles. The ... months. This means that people who are conscious about their ...

(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...

Breaking Medicine News(10 mins):Health News:Glaucoma drug can cause droopy eyelids 2 Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2 Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2

[0] Glaucoma drug can cause droopy eyelids [0] Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives [0] Post-approval TAVI registry shows high rates of device success at 1 year [0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?[0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference

... Hospital,of Chicago (NOHC) is among the top five percent in ... Hospital Quality in,America study. The HealthGrades Research analyzed patient outcomes ... The study also,concluded that NOHC is:, -- ... A recipient of the HealthGrades Spine Surgery Excellence Award ...

... Facility is First New Maine Hospital in ... Global Med Technologies(R),Inc. (OTC Bulletin Board: GLOB), ... today that its Wyndgate,Technologies(R) division has signed ... of Brunswick, Maine, to license its SafeTrace ...

... between NanoHorizons and Hill-Rom delivers patient support ... with revolutionary antimicrobial technology, BATESVILLE, Ind., ... announced an agreement to incorporate,NanoHorizon,s antimicrobial technology ... be branded as "nanoAg+ (TM) with,SmartSilver(TM)", will ...

... new guideline on colorectal cancer screening released today ... of health care organizations, including the American College ... Endoscopy (ASGE) and the American Cancer Society (ACS), ... detection and states a strong preference for screening ...

... Naval Medical Center in Bethesda, Maryland Coincides, With Sleep Apnea ... ... Awareness Week, DALLAS, March 6 /PRNewswire/ - The observance ... for Dr. Keith Thornton,third-generation Dallas dentist and recognized expert on the treatment ...

... General Nutrition Centers, Inc.,("GNC" or the "Company"), the ... its financial results for the,quarter and year ended ... is an indirect wholly-owned subsidiary,of GNC Parent LLC, ... affiliates of,Ares Management LLC and Ontario Teachers, Pension ...

Neurologic & Orthopedic Hospital of Chicago Ranked Among Top in Nation for Spine Surgery Newest Hospital in New England Signs Agreement With Global Med Technologies(R), Inc.Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology New guidelines update recommendations on colorectal cancer screening Dallas Dentist Trains Navy Dentists on New Therapy to Treat Snoring and Obstructive Sleep Apnea General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results

... The CritSpin whisper quiet, compact system ... clinic anywhere fast, accurate and cost effective ... Digital Reader, the CritSpin System offers a ... spin, complete cell packing - Meets NCCLS ...

... light over one smooth pulse duration, rather ... damage skin) that other technologies use. Palomar's ... water supply through the StarLux handpiece, down ... to as low as 4 degrees C. ...

Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...

Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....

Medicine Products:

CritSpin Microhematocrit Centrifuge StarLux Pulsed Light and Laser System Silicone Foley Silicone Universal Drainage Stents